Newlink Genetics Corporation
(NASDAQ : NLNK)

( )
NLNK After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Loading NLNK News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
4.42%70.480.9%$642.57m
CELGCelgene Corporation
0.64%133.681.1%$633.67m
AMGNAmgen Inc.
1.44%173.821.1%$633.64m
ALXNAlexion Pharmaceuticals, Inc.
2.14%126.231.9%$553.94m
REGNRegeneron Pharmaceuticals, Inc.
0.86%526.532.7%$546.91m
BIIBBiogen Inc.
0.71%280.571.2%$499.28m
VRTXVertex Pharmaceuticals Incorporated
0.52%135.531.9%$281.36m
INCYIncyte Corporation
1.22%135.632.6%$274.50m
CLVSClovis Oncology, Inc.
2.64%96.7818.0%$248.18m
TSROTESARO, Inc.
5.38%149.7714.7%$231.38m
PBYIPuma Biotechnology, Inc.
7.73%86.4521.1%$188.33m
ILMNIllumina, Inc.
3.16%182.993.5%$163.69m
BLUEBluebird Bio, Inc.
-1.50%118.5019.3%$156.72m
AAgilent Technologies, Inc.
1.36%60.601.5%$134.46m
EXASExact Sciences Corporation
-0.80%34.7126.3%$127.68m

Company Profile

NewLink Genetics Corp. is a clinical stage immuno-oncology company, which focuses on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. The company's products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189 and IDO Pathway Inhibitors. NewLink Genetics was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.,003KPN-E